Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

Abstract

Udgivelsesdato: 2008-Sep

Shown for reading. Its publisher allows quoting it, not republishing it.

References 6

1. 1.

   Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J, et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with Type 2 diabetes. Diabetes Care. 2007;30:1608-1610.

   Not in our library10.2337/dc06-2593

2. 2.

   Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue improves β-cell function and arginine-stimulated insulin secretion at hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med. 2008;25:152-156.

   Not in our library10.1111/j.1464-5491.2007.02333.x

3. 3.

   Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Ryden L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with Type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res. 2004;1:40-43.

   Not in our library10.3132/dvdr.2004.005

4. 4.

   Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, et al. Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-E1215.

   Not in our library10.1152/ajpendo.00237.2004

5. 5.

   Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97:3-11.

   Not in our library10.1016/j.amjcard.2005.11.010

6. 6.

   Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with Type 2 diabetes and microalbuminuria. Diabetologia. 2005;48:3-5.

   Not in our library10.1007/s00125-004-1607-0

Cited by papers we hold 1

• The Discovery and Development of Liraglutide and Semaglutide · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.